Ginkgo Bioworks, an Boston, MA-based organism design company, raised $100m in Series C round of funding.
Backers included Y Combinator’s Continuity Fund, Senator Investment Group, Cascade Investment, Baillie Gifford, Viking Global Investors and Allen & Company LLC.
The company, which has raised $154illion in the past 15 months, intends to use the funds to grow into new markets, such as commodity chemicals, industrial enzymes and human health markets, as well as to build its automated foundry, Bioworks2, where Ginkgo’s organism engineers can develop new designs at massive scale.
Founded in 2008 by Tom Knight, a computer scientist, and MIT biological engineering PhDs Jason Kelly, Reshma Shetty, Barry Canton and Austin Che, Ginkgo Bioworks is building organisms to specification for customers across a variety of markets including food, health, and consumer goods.
The company’s organism engineers work directly with customers, including Fortune 500 companies, to design microbes for their specific needs.
In addition to the funding, Ginkgo has partnered with Twist Bioscience and Gen9, providers of synthetic DNA, to have a 600 million base pairs of DNA manufactured, the raw material for its biological prototypes, which will be used to generate genetic designs that will be built and tested in its new foundry, Bioworks2.
SOURCE Ginkgo Bioworks